Evidence map›Paper›PMID 39526809›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Assessment of Single-Cycle M-Protein Mutated Vesicular Stomatitis Virus as a Safe and Immunogenic Mucosal Vaccine Platform for SARS-CoV-2 Immunogen Delivery.

En Zhang, Yong Ke, Weihong Ran, Yu Zhang, Ruihang Li, Xinkui Fang, Lei Wang, Baohong Zhang, Tao Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

En ZhangSchool of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, 200240, China.
Yong KeEngineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Dongchuan Road, Minhang District, Shanghai, 200240, China.
Weihong RanSchool of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, 200240, China.
Yu ZhangSchool of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, 200240, China.
Ruihang LiSchool of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, 200240, China.
Xinkui FangSchool of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, 200240, China.
Lei WangEngineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Dongchuan Road, Minhang District, Shanghai, 200240, China.
Baohong ZhangEngineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Dongchuan Road, Minhang District, Shanghai, 200240, China.
Tao SunSchool of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, 200240, China.ORCID 0000-0002-8455-809X

Funding

Biomedicine and Technology Supporting Project of the Shanghai Science and Technology Innovation Plan 20S11904900Biomedicine and Technology Supporting Project of the Shanghai Science and Technology Innovation Plan 22S11902200
6 · The paper itself

Abstract

The goal of the next-generation COVID-19 vaccine is to provide rapid respiratory tract protection with a single dose. Circulating antibodies do not protect the olfactory mucosa from viral infection, necessitating localized mucosal immunization. Live attenuated vesicular stomatitis virus (VSV

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-2AnimalsAntibodies, NeutralizingAntibodies, ViralHumansImmunity, MucosalMiceMutationSpike Glycoprotein, CoronavirusVaccines, AttenuatedVesicular stomatitis Indiana virusVesiculovirusViral Matrix ProteinsAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, AttenuatedViral Matrix ProteinsCOVID‐19mucosal immunityreplication defectiveSpike proteinvesicular stomatitis virus

Identifiers

PMID39526809
PMCPMC11653642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.